In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Beyond semaglutide and tirzepatide, where might we find the next GLP 1 based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and MAA Semaglutide and Cagrilintide vs Tirzepatide.docx CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn